Altis Team


Michael Biron
CEO & Co-Founder

Michael Biron, MBA, is the CEO, co-founder and Chairman of the Board 
of Altis Biosystems. He is a former U.S. Army Officer, with experience in project management, logistics, and leadership development. Prior to the military, Michael spent several years as a top sales representative. He also worked in project management and was responsible for overseeing 
a variety of projects valued up to $26M. Michael has a Bachelor’s degree from Penn State and an MBA from UNC Kenan-Flagler Business School, with a concentration in entrepreneurship.


Christopher Sims, MD
President & Co-Founder

Dr. Christopher Sims, MD, is the President and a co-founder of Altis Biosystems and is a Professor at the University of Washington. He holds 
a BS in Physical Sciences (Chemistry) from Auburn University and an MD from Johns Hopkins University. He completed a medical residency at the Beth Israel Hospital, Harvard University, and postdoctoral clinical fellowships in medicine and in rheumatology at Stanford University Hospital. His postdoctoral research work was in Physiology and Biophysics at the University of California, Irvine where he remained on faculty until his move to UNC-Chapel Hill in 2007. His current research is aimed at the development of cell-based assays and microfabricated technologies for clinical and biomedical applications, particularly in the field of stem cell research. Dr. Sims has been the scientific co-founder of three prior companies: Cell Biosciences (currently Protein Simple); Intellego, Inc.; and Cell Microsystems, Inc.

Chielf Scientific Officer

Bill Thelin, Ph.D
Chief Scientific Officer

Bill Thelin, Ph.D. is the Chief Scientific Officer at Altis Biosystems. He has more that 15 years of drug development experience, overseeing preclinical from discovery to IND-filing. Prior to joining Altis, Bill served as the Vice President of Research at Parion Sciences. In his tenure at Parion, he helped to build a portfolio of novel, first-in-class therapeutic programs for pulmonary and ophthalmic diseases, which collectively raised >$150M in non-dilutive funding through NIH grants and corporate partnerships. He received a Ph.D. in Cell Biology at the University of North Carolina and was a postdoctoral fellow with Dr. Richard Boucher at the UNC Cystic Fibrosis Center. Prior to Altis, his scientific expertise focused on epithelial ion channel and receptor pharmacology, mucosal disease, and targeted drug discovery.


Ron Laethem, Ph.D.
Director of Biology

Ron Laethem, Ph.D., is the Director of Biology at Altis Biosystems and is a drug disposition scientist with nearly 30 years of experience in the pharmaceutical and biotechnology areas with expertise carrying out in vitro ADME studies. Ron comes to Altis Biosystems from BioIVT where he was the Director of ADME Services Operations, responsible for setting up and overseeing the in vitro ADME group focusing on non-GLP, drug-drug interaction studies for IND and NDA filings.


Niki Heinz
Director of Business Development

Niki Heinz is the Business Development Director at Altis Biosystems and has been successfully selling into the pharmaceutical and biotechnology research space for over 10 years. Niki formerly worked for Asterand Bioscience and BioIVT and has also worked as a QC and R&D chemist in the detergent industry, as well as with the Michigan Department of Natural Resources as a Naturalist. Niki has a BS in Biology and is an active member of the Henry Ford College Biotechnology Advisory Board.